

Bulletin #816

July 11, 2011

## **NBPDP FORMULARY UPDATE**

This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective July 11, 2011

**Included in this bulletin:**

- **Regular Benefit Additions**
- **Special Authorization Additions**
- **Drugs Reviewed and Not Listed**
- **Reimbursement of brand name products when generic products exist**

To subscribe or unsubscribe from the Bulletin e-mail notification list, please send a message to [BC\\_nbpdp@medavie.bluecross.ca](mailto:BC_nbpdp@medavie.bluecross.ca) or call 1-800-332-3691. Bulletins are also available on the NBPDP web page: [www.gnb.ca/0051/0212/index-e.asp](http://www.gnb.ca/0051/0212/index-e.asp)

If you have any questions, please contact our office at 1-800-332-3691.

## REGULAR BENEFIT ADDITIONS

Drug/Form/Route/Strength	Brand Name	DIN	Manufacturer	Plans	\$
<b>Degarelix</b> Pws SC					
80mg/vial	Firmagon®	02337029	FEI	AEF+18VW	AAC
120mg/vial	Firmagon®	02337037			
<b>Piperacillin/Tazobactam</b> Pws Inj					
2g/0.25g	Tazocin®	02170817	PFI		
	Piperacillin/Tazobactam	02308444	APX	W	MAP
	Piperacillin/Tazobactam	02299623	SDZ		
3g/0.375g	Tazocin®	02170795	PFI		
	Piperacillin/Tazobactam	02308452	APX	W	MAP
	Piperacillin/Tazobactam	02299631	SDZ		
4g/0.5g	Tazocin®	02170809	PFI		
	Piperacillin/Tazobactam	02308460	APX	W	MAP
	Piperacillin/Tazobactam	02299658	SDZ		

## SPECIAL AUTHORIZATION ADDITIONS

**Everolimus**  
(*Afinitor*®)  
10mg tablets

For the treatment of patients with metastatic renal cell carcinoma of clear cell morphology, as second or third-line therapy after failure of initial treatment with either of the VEGF-receptor tyrosine kinase inhibitors (sunitinib or sorafenib).

**Nilotinib**  
(*Tasigna*®)  
200mg capsules

For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in adult patients who:

- are resistant or intolerant to imatinib, or
- intolerant to dasatinib

## DRUGS REVIEWED AND NOT LISTED

The review of the following products found they did not offer a therapeutic and/or cost advantage over existing therapies. Requests for special authorization will not be considered.

**Capecitabine** - For treatment of metastatic gastric cancer in combination with trastuzumab

(*Xeloda*®)

150mg, 500mg tablets

**Gefitinib** - For first line treatment of non-small cell lung cancer

(*Iressa*®)

250mg tablets

## REIMBURSEMENT OF BRAND NAME PRODUCTS WHEN GENERICS EXIST

When interchangeable generic products are available for a brand name drug, the New Brunswick Prescription Drug Program (NBPDP) will only reimburse pharmacies for the lowest cost generic product. Beneficiaries, who choose to receive a brand name product when a generic product exists, are responsible for paying any difference in price.

The NBPDP will consider requests for reimbursement of brand name drugs when a beneficiary has had a hypersensitivity reaction (e.g. edema, respiratory distress, serum sickness, anaphylaxis) to a non-medicinal ingredient contained in the interchangeable generic product. Requests may be made by submitting a completed [Special Authorization Request Form](#) and providing details of the hypersensitivity reaction.

Information on the safety and effectiveness of generic drugs is available on Health Canada's website at <http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/med-gen-eng.php>.